Alto Neuroscience, INC Form 4 insider transactions

Christopher Nixon Cox, a director at Alto Neuroscience, acquired stock options for 25,236 shares in lieu of $80,000 in retainer fees.

Adam Savitz, Chief Medical Officer of Alto Neuroscience, recently increased his indirect holdings in the company's common stock through purchases made via a trust.

Michael Hanley Jr., COO of Alto Neuroscience, reported the acquisition of stock options for 188,000 shares of common stock.

Nicholas Conrad Smith, CFO of Alto Neuroscience, recently acquired additional shares of the company's common stock through open market purchases.

Director Radhakrishnan Maha acquired stock options in Alto Neuroscience, Inc. on March 8, 2024, as part of their compensation.

Apeiron Investment Group and related entities report changes in beneficial ownership of Alto Neuroscience's stock following the company's initial public offering, including conversions of preferred stock and warrants into common stock.

Adam Savitz, Chief Medical Officer of Alto Neuroscience, reported the acquisition of stock options on March 1, 2024.

CEO Amit Etkin reports acquisition of shares and options in Alto Neuroscience, signaling continued involvement and investment in the company.

Nicholas Conrad Smith, CFO of Alto Neuroscience, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.